FATE - Fate: Possible Speedy FDA Approval Process With RMAT Designation
- Meeting with FDA set for mid-2022 to discuss potential to begin pivotal trial using FT516 for patients with relapsed/refractory diffuse large B-cell lymphoma.
- If all goes well with FDA meeting for FT516, then a pivotal study should begin in the second half of 2022.
- FT516 is being explored for many other types of relapsed/refractory lymphomas besides diffuse large B-cell lymphoma.
- FT596 is another shot on goal in the pipeline being explored for the treatment of patients with relapsed/refractory lymphomas.
For further details see:
Fate: Possible Speedy FDA Approval Process With RMAT Designation